newsfilter
← Latest News
GlobeNewswire·

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin's Lymphoma who relapsed after